anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hepatocellular carcinoma (HCC) is a highly lethal cancer, and proteomic studies have shown increased protein diversity and abundance in HCC tissues, whereas the role of protein translation has not been extensively explored in HCC. Our research focused on key molecules in the translation process to identify a potential contributor in HCC. We discovered that EIF4G2, a crucial translation initiation factor, is significantly upregulated in HCC tissues and associated with poor prognosis. This study uniquely highlights the impact of EIF4G2 deletion, which suppresses tumor growth and metastasis both in vitro and in vivo. Furthermore, polysome analysis and nascent protein synthesis assays revealed EIF4G2's role in regulating protein translation, specifically identifying PLEKHA1 as a key translational product. This represents a novel mechanistic insight into HCC malignancy. RNA immunoprecipitation (RIP) and Dual-luciferase reporter assays further revealed that EIF4G2 facilitates PLEKHA1 translation via an IRES-dependent manner. Importantly, the synergistic effects of EIF4G2 depletion and PLEKHA1 reduction in inhibiting cell migration and invasion underscore the therapeutic potential of targeting this axis. This study not only advances our understanding of translational regulation in HCC but also identifies the EIF4G2-PLEKHA1 axis as a promising therapeutic target, offering new avenues for intervention in HCC treatment.
PURPOSE:To obtain a new LPS having high immunological function activating ability, extremely low toxicity, high chemotherapy coefficient, usable for a long period of time, capable of being administered through oral, percutaneous or injection route and being supplied in a large amount at low manufacturing cost, a new bacterium to produce the LPS, a new immunological function activator containing the LPS and an immunological function activator for animal. CONSTITUTION:This LPS has the following physical properties and the bacterium produces the LPS. Molecular weight: 5,000+ or -1,500 (by tricine-SDS-PAGE method). The number of mole of phosphorus: 2.0+ or - 1/molecular weight 5,000. The number of mols of hexosamine: 9.1+ or -1/molecular weight 5,000. The number of mols of KDO: 0.8+ or -0.5/molecular weight 5,000.
The aim of this study is to determine the prevalence of taste alterations (TAs) during chemotherapy and their association with nutritional status and malnutrition. In addition to the associated factors with TA, including sociodemographic health-related factors and clinical status, and to investigate coping strategies to manage TA. A multicenter cross-sectional design study was conducted on 120 cancer patients aged at least 18 who had been undergoing at least one round of chemotherapy. TAs were evaluated using the chemotherapy-induced taste alteration scale (CiTAS), the malnutrition universal screening tool (MUST) was used for nutritional screening, the antineoplastic side effects scale (ASES) was used for subjective assessment of chemotherapy side effects, and the Charlson comorbidity index (CCI) was used for comorbidity assessment. SPSS21 software was used to analyze the data, and the independent T-test and one-way ANOVA test were used to determine the association between TAs and a variety of related variables. The prevalence of TAs was 98.3%. Among participants, 48.3% were at low risk of malnutrition, 20% at medium risk, and 31.7% at high risk. Malnutrition risk was associated with taste disorders (p<0.05). Patients' age, gender, educational level, and physical status were associated with TAs (p<0.05). Type of cancer, chemotherapy regimen, and number of chemotherapy cycles were also associated with TAs (p<0.05). A variety of antineoplastic side effects were associated with TAs (p<0.05), including nausea, vomiting, dry mouth, sore mouth and throat, excessive thirst, swallowing difficulty, appetite changes, weight loss, dizziness, lack of energy, disturbed sleep, anxiety, and difficulty concentrating. TAs were associated with an increased number of comorbidities, and individuals with diabetes, pulmonary diseases, and hypertension were associated with TAs (P<0.05). Patients in this study rarely practice self-management strategies to cope with TAs. A high prevalence (98.3%) of TAs in cancer patients receiving chemotherapy was found, and it was linked to a variety of negative outcomes. Chemotherapy-induced TAs are an underestimated side effect that requires more attention from patients and health care providers.
Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.
Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Household-specific water quality information will be delivered to households within 72 hours, and households will be informed whether their drinking water was found to be contaminated. A study team member will review the information from the laboratory tests with the household and review information covered in the informational materials on safe water handling, storage, and use behaviours.
Systems and methods for designing and implementing patient-specific surgical procedures and/or medical devices are disclosed. In some embodiments, a method includes receiving a patient data set of a patient. The patient data set is compared to a plurality of reference patient data sets, wherein each of the plurality of reference patient data sets is associated with a corresponding reference patient. A subset of the plurality of reference patient data sets is selected based, at least partly, on similarity to the patient data set and treatment outcome of the corresponding reference patient. Based on the selected subset, at least one surgical procedure or medical device design for treating the patient is generated. In some embodiments, the at least one surgical procedure or medical device design can be used to treat the patient's pelvic region and/or sacroiliac joint.
The invention relates to the production of a silicate having the properties which are similar to the properties of a talcum powder. Said invention makes it possible to produce the silicate (the general formula n*SixOy*z) which can be used instead of natural talc, and to produce substances of various classes based thereon, for example antiseptics, sorbents etc. The inventive method consists in the following: a crushed raw material or crushed glass is treated by water or solutions having an acid or neutral reaction, until pH reaches a value equal to or less than seven in a surface layer of particles of the obtainable product. Afterwards, said particles are removed from the obtained solution. The crushed raw material or crushed glass can also be treated by water or solutions having an alkaline reaction, until pH reaches a value  equal to or less than seven in a surface layer of particles of the obtainable product. Afterwards, said particles are removed from the obtained solution. The methods for drying the obtainable product and cleaning the raw material are also disclosed.
Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
TUXARIN ER contains codeine, a Schedule III controlled substance. As an opioid, TUXARIN ER exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)], which can lead to overdose and death [see Overdosage (10)]. Reserve TUXARIN ER for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient's risk prior to prescribing TUXARIN ER, prescribe TUXARIN ER for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addiction or abuse, and refill only after reevaluation of the need for continued treatment.

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed TUXARIN ER. Addiction can occur at recommended dosages and if the drug is misused or abused. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing TUXARIN ER. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see Patient Counseling Information (17)]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
PURPOSE:To provide the titled promoting agent containing dolichol or its ester as an active component, effective to promote the differentiation and proliferation of hematopoietic stem cell and improve the hematopoiesis-promoting effect of hematopoietic stimulation hormone, and useful for the remedy of senile anemia, hematopoietic function disorder, etc. CONSTITUTION:The objective agent for promoting the differentiation and proliferation of hematopoietic stem cell contains the dolichol of formula I (the group of formula II is trans-isoprene unit; the group of formula III is cis-isoprene unit; n is integer of 12-18) and/or its ester, as an active component. The compound of formula I is effective to promote the differentiation and proliferation of hematopoietic stem cell, and to cover and improve the hematopoiesis promoting effect of hematopoietic stimulation hormone (e.g. erythropoietin, colony stimulation factor, etc.). Furthermore, it has low side effect and toxicity, and is useful for the remedy of senile anemia caused by the lowering of the hematopoietic function, hematopoietic function disorder and aplastic anemia, etc. caused by the administration of carcinostatic agent or radiotherapy, etc.
OBJECTIVE: To assess the effects of diode-pumped solid-state laser irradiation with 589nm and 650nm wavelengths on the stability of stored red blood cells in vitro.
METHODS: This is an intervention study that was conducted from April to July 2021 at the Physiology and Medical Physics Laboratory, College of Medicine, Mustansiriyah University, Baghdad, Iraq, and comprised samples of healthy, adult human blood that were put in tubes with citrate-phosphate dextrose-adenine as an anticoagulant. The blood sample was divided into eight equal aliquots and stored for 21 days at 4ºC. The stability test was done on days 0, 7, 14 and 21 of storage time for non-irradiated and radiated aliquots. For 15 minutes, the irradiated aliquots were subjected to a diode-pumped solid-state laser with a wavelength of 589nm or a laser with a wavelength of 650nm at frequencies of 30, 50 and 70 J/cm². Data was analysed using SPSS 24.
RESULTS: Exposure of the whole blood to 589nm and a radiation dose of 70J/cm², 50J/cm² and 30J/cm² was associated with a significant reduction in the percentage of haemolysis that ranged 23-42% throughout the whole storage time. Exposure of the whole blood to 650nm wavelength low-level laser therapy and a radiation dose of 70J/cm², 50J/cm² and 30J/cm² was associated with much less reduction in the percentage of haemolysis that ranged 5-9% throughout the whole storage time.
CONCLUSIONS: Both 589nm and to some extent 650nm low-level laser irradiation generally reduced haemolysis. The wavelength of 589nm lasers had a more effective influence than the 650nm counterpart in improving the stored red blood cells.
Biofilms are complex bacterial communities characterized by a high persister prevalence, which contributes to chronic and relapsing infections. Historically, persister formation in biofilms has been linked to constraints imposed by their dense structures. However, we observed an elevated persister frequency accompanying the stage of cell adhesion, marking the onset of biofilm development. Subsequent mechanistic studies uncovered a comparable type of toxin-antitoxin (TA) module (TA-like system) triggered by cell adhesion, which is responsible for this elevation. In this module, the toxin HipH acts as a genotoxic deoxyribonuclease, inducing DNA double strand breaks and genome instability. While the second messenger c-di-GMP functions as the antitoxin, exerting control over HipH expression and activity. The dynamic interplay between c-di-GMP and HipH levels emerges as a crucial determinant governing genome stability and persister generation within biofilms. These findings unveil a unique TA system, where small molecules act as the antitoxin, outlining a biofilm-specific molecular mechanism influencing genome stability and antibiotic persistence, with potential implications for treating biofilm infections.
All patients with a significant stenosis (\>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
PURPOSE: A cosmetic composition for relieving atopic dermatitis containing Brandisia hancei Hook extract is provided to suppress generation of NO, prostaglandin E2(PGE2) and interleukin-6 without cytotoxicity. CONSTITUTION: A cosmetic composition for relieving atopic dermatitis contains Brandisia hancei Hook extract as an active ingredient. The Brandisia hancei Hook extract is obtained by drying, pulverizing, extracting with a solvent, filtering, and concentrating. The extraction solvent is water, low alcohol of C1-C3 or mixture solution thereof. The extraction is performed by heat extraction, reflux extraction, and ultrasonic wave extraction. The cosmetic composition is used in the form of ointment, lotion, cream, essence, lotion, soap, pack or patch.
Concussions affect thousands of Canadians every year. Although the effects are usually temporary, 10-15% of adults experience persistent symptoms likely to last several weeks or even months. Some studies have explored the impact of pharmaceuticals on treating post-concussive symptoms. Still, these have shown little success, leading the scientific community to consider multidisciplinary approaches to treating and managing concussions. Recently, it has been suggested that nutritional interventions should be considered in concussion management because nutrition can act on several mechanisms of brain injury. Some nutritional supplements have shown beneficial effects on the speed of recovery and the degree of severity of symptoms related to moderate or severe head trauma. Other studies have shown a link between malnutrition and low neurological and cognitive scores. However, to date, no study has assessed the impact of dietary interventions on the recovery of people with persistent post-concussive symptoms.

This randomized controlled trial aims to determine the impact of a dietary and nutritional intervention on the physical, cognitive, behavioural and emotional symptoms of patients with persistent post-concussive symptoms in New Brunswick, Canada. Patients will be randomized to one of three groups: 1) dietary treatments and nutritional supplements (experimental group A), 2) nutritional supplements (experimental group B), and 3) physiotherapy treatments (control group). Patients in group A will receive four consultations with a dietitian over eight weeks, in addition to conventional physiotherapy treatments. These patients will receive nutritional counselling and omega-3, vitamin D and creatine supplements. Patients in group B will be prescribed the same supplements as those in group A by their doctor and receive physiotherapy treatments. Finally, patients in the control group will only receive physiotherapy treatments. The use of three groups will help determine the individual impact of dietetic treatment offered by a dietitian and the use of supplements. Patient symptoms will be measured using a questionnaire constructed from tools commonly used in practice by medical doctors, physiotherapists and dietitians. This questionnaire will be completed at the first physiotherapy session and 2, 4 and 8 weeks after the start of the intervention.
PURPOSE: In contrast to the extensive literature on fear of cancer recurrence (FCR) experienced by adults, literature evaluating pediatric FCR has just begun to emerge. Given the rapidly expanding body of work assessing FCR in childhood and adolescence, a scoping review was conducted to synthesize existing findings. We aimed to assess (1) the characteristics and methods of this literature, (2) how pediatric FCR has been measured, and (3) the extant knowledge of FCR experienced by pediatric survivors of cancer.
METHODS: Inclusion criteria were: (1) original reports, (2) participants diagnosed with cancer before age 18, (3) current mean age under 18, (4) FCR was explicitly measured (quantitatively) or captured (qualitatively) via survivor self-report, and (6) published in English. Exclusion criteria were: (1) case studies, and (2) grey literature. Three databases (Embase, MEDLINE, PsycINFO) and reference lists from included studies were searched. All studies were screened for inclusion by two authors and all data were extracted by a single author.
RESULTS: Of 3906 identified studies, 19 were included. Studies (published 1991 - 2023) encompassed diverse geographical locations, study designs, and measurement methods. Few assessed FCR as a primary aim (n = 6, 32%). FCR was experienced by 43 - 90% of pediatric survivors. FCR was often positively associated with somatic symptoms and negatively associated with quality of life and emotional functioning.
CONCLUSION: FCR is a prevalent issue for children and adolescents. Additional evidence is needed to explore and confirm preliminary findings. Future pediatric FCR studies should aim to align with published priority research areas.
OBJECTIVE: Noninvasive mechanical ventilation (NIMV) improves amyotrophic lateral sclerosis (ALS) quality of life and survival. However, data about its effect on disease progression are still lacking. Here, we test whether NIMV use changed the rate of functional decline among ALS patients.
METHODS: In this retrospective observational study, we included 448 ALS patients followed up at the ALS Center in Turin, Italy, who underwent NIMV during the disease course. The primary outcome was the change in functional decline after NIMV initiation adjusting for covariates. Functional decline was based on the nonrespiratory items of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R).
RESULTS: NIMV initiation resulted in a slower functional decline (mean improvement = 0.16 points per month, 95% confidence interval = 0.12-0.19, p < 0.001), with consistent effects observed across various demographic factors, including sex, age at diagnosis, and disease duration before NIMV initiation. This finding was replicated using the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) dataset. The favorable impact of NIMV on ALSFRS-R progression was evident independently of disease stages. Notably, NIMV benefits were not dose-dependent but were particularly prominent for nighttime respiratory support.
INTERPRETATION: NIMV significantly influences the rate of motor progression in ALS, and this effect is not determined by the nonlinearity of ALSFRS-R trajectory. The functional decline slowed following NIMV initiation, independently of the site of disease onset or disease severity at the time of NIMV initiation. Our findings underscore the importance of timely NIMV initiation for all ALS patients and highlight the need to consider NIMV-induced slowing of disease progression when evaluating clinical trial outcomes. ANN NEUROL 2024;95:817-822.
A tincture composition includes gel-free sea moss extract; about 80-90% by volume glycerin; about 10-18% by volume ethanol; and about 0.5-1.5% cinnamon oil. The total amount of glycerin, ethanol, and cinnamon oil is 100%. A method of producing the composition includes soaking sea moss in water; drying the sea moss; immersing the sea moss fully in glycerin; providing an extraction blend; blending the sea moss, the glycerin, and the extraction blend to form a suspension; straining the suspension to extract a tincture; and heating the tincture at 50-200 degrees Fahrenheit for 1-24 hours. The extraction blend includes, per 1 part by volume glycerin: 1/16 to 2 parts by volume ethanol and 1/100 to ¼ parts by volume of cinnamon oil. The tincture composition has an excellent shelf life and improved palatability. A binding agent may be added to prevent separation.
In clinical studies with finasteride tablets in men 18 to 41 years of age, the mean value of serum prostate specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12. Further, in clinical studies with finasteride tablets, 5 mg when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%. Other studies with finasteride tablets, 5 mg showed it may also cause decreases in serum PSA in the presence of prostate cancer. These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride. Any confirmed increase from the lowest PSA value while on finasteride tablets may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α-reductase inhibitor. Non-compliance to therapy with finasteride tablets may also affect PSA test results.
NEW MATERIAL:A protein obtained from epidermal part of rice. Elementary analysis (%); C, 52.3+ or -2.1; H, 8+ or -0.3; N, 10+ or -1. Molecular weight; 13,000 measured by gel filtration in the presence of a surfactant. Solubility; Soluble in water, acetic acid, pyridine, etc., and insoluble in acetone, ethyl acetate, etc. Color reactions; Positive to biuret reaction and negative to phenol-sulfuric acid reaction, etc. Amino acid composition (molar ratio); Asp 5-9, Ile 6-10, etc. Melting point; Browning at 240 deg.C and decomposing at 270 deg.C. USE:An antitumor agent. PREPARATION:The epidermal part of rice seeds is initially extracted with a basic aqueous solution and a polar organic solvent is added to the resultant extract solution. The above-mentioned supernatant part is then neutralized with an acid and the obtained precipitate part is extracted with an alkali in an alcohol while heating. The resultant extract solution is evaporated to dryness to afford a solid substance, which is then dissolved in water and neutralized with an acid. The formed precipitates are subsequently adsorbed on a basic ion exchange resin and then eluted to provided a protein-containing eluate, which is purified by hydrophobic chromatography.